Starling Oncology, Inc. STLN
4.20 USD -0.14 (-3.23%)
At closeNov 12, 2026, 4:25 AM EST
4.16 -0.04 -0.95%
Pre-market · Nov 12, 4:25 AM ET
4.16 Day range 4.71
2.32 52-week range 7.13
- YTD
- +17.98%
- 1 year
- +25.00%
News
seekingalpha.com Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript
benzinga.com B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.
marketbeat.com Oncology Institute Q3 Earnings Call Highlights Oncology Institute NASDAQ: STLN, referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10 BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.
zacks.com Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates Starling Oncology, Inc. (STLN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
benzinga.com Starling Oncology Q3 2026 Earnings Call Transcript Starling Oncology (NASDAQ:STLN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
benzinga.com Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of…
globenewswire.com Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States,…- benzinga.com Needham Maintains Buy on Starling Oncology, Raises Price Target to $9 Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.